ALLR Stock Summary and Trading Ideas (Allarity Therapeutics | NASDAQ:ALLR)

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Allarity Therapeutics trades on the NASDAQ stock market under the symbol ALLR.

As of March 3, 2025, ALLR stock price climbed to $0.88 with 7,733,839 million shares trading.

ALLR has a beta of 2.28, meaning it tends to be more sensitive to market movements. ALLR has a correlation of 0.04 to the broad based SPY ETF.

ALLR has a market cap of $3.90 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ALLR traded as high as $3,653,999.00 and as low as $.68.

ALLR has underperformed the market in the last year with a price return of -99.7% while the SPY ETF gained +16.7%. ALLR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -20.7% and -10.0%, respectively, while the SPY returned -2.2% and -4.3%, respectively.

ALLR support price is $.74 and resistance is $.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALLR shares will trade within this expected range on the day.